Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05603104). This is a study registration, not published results. Lead sponsor: Dr. Inge Winter. Recruitment status: TERMINATED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1 participants (ACTUAL). Conditions: Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression. Interventions: DRUG: Clozapine; DRUG: Esketamine Nasal Product; DRUG: Escitalopram; DRUG: Sertraline; DRUG: Venlafaxine; DRUG: Lithium; DRUG: Valproate acid; DRUG: Quetiapine; DRUG: Second-line Antidepressants; DRUG: Second-line Antipsychotics; DRUG: Ketamine Hydrochloride; DRUG: Esketamine hydrochloride; DRUG: Bupropion. Primary outcome measures: Change in symptom severity , 6 weeks. Brief summary: Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) when used earlier in the disease course for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.